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Advances in targeted immune therapeutics have profoundly improved clinical outcomes
for patients with inflammatory arthropathies particularly rheumatoid arthritis. The land-
scape of disease that is observed and the treatment outcomes desired for the future have
also progressed. As such there is an increasing move away from traditional models of
end-stage, chronic disease with recognition of the need to consider the earliest phases
of pathogenesis as a target for treatment leading to resolution and/or cure. In order to
continue the discovery process and enhance our understanding of disease and treatment,
we therefore need to continuously revisit the animal models we employ and assess their
relevance and utility in the light of contemporary therapeutic goals. In this review, we
highlight the areas where we consider new developments in animal models and their
application are most required. Thus, we have contextualised the relevant mouse models
and their use within the current concepts of human inflammatory arthritis pathogenesis
and highlight areas of need.
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Introduction
Rheumatoid arthritis (RA) is a prototypic inflammatory arthritis
– it is a chronic, painful and disabling inflammatory disease prin-
cipally resulting in damage to joints and surrounding connective
tissues. The processes underlying initiation and perpetuation of
disease involve a complex interplay between genetic and environ-
mental factors. Consequently, current research focuses on how
these factors lead to perturbations in innate and adaptive immune
responses, changes in tissue stroma activity, and ultimately to joint
disease. Our current knowledge can be summarised in a step-
wise pathogenesis map that depicts distinct phases or processes
in RA [1–3]. In the first, genetic and environmental factors con-
tribute to an underlying breach of self-tolerance in the absence
of overt clinical manifestation. This early autoreactivity is evi-
denced by the presence of rheumatoid factor and anti-citrullinated
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peptide antibodies (ACPA) several years prior to emerging tissue
pathology [4]. Changes in the glycosylation of APCA Fc precede
early signs of synovitis and articular damage [5], marking transi-
tion to the second stage. Although the events driving this transi-
tion remain ill defined, neurovascular, microtrauma or infection
dependent mechanisms have been proposed as triggers of syn-
ovitis. Finally, perpetuation of inflammation occurs that leads to
articular damage typical of chronic established RA and to atten-
dant co-morbidities.
The continuing elucidation of the pathogenesis map relies on
data obtained from clinical and animal model studies. Debate over
the validity of animal models can arise when contrasting results
arise from human studies, questioning the validity of animal mod-
els. The publication of data stating mouse models poorly reflect
human genomic inflammatory responses [6] and associated media
coverage has further fueled this debate. However, reassessment of
the same dataset later demonstrated clear correlations between
mouse and human responses [7], highlighting the importance of
careful model selection and data analysis for interpretation in
the context of human pathology. Animal models have been, and
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continue to be, essential in testing hypotheses and defining biolog-
ical mediators and cellular processes involved in human disease.
In this regard, their continued importance has been highlighted
recently [8–11]. Here we contextualise animal models in line with
current RA pathogenesis concepts and highlight areas of unmet
need.
Informed model selection
It is clearly unrealistic to expect a single model of arthritis to
fully recapitulate human disease. However, individually they allow
molecular and spatiotemporal dissection of various pathological
processes of RA development that would otherwise be imprac-
tical, or unethical in a clinical setting. Employing combinations
of models offers the potential to better mirror the complexities
of human disease, reflecting different environmental, genetic and
temporal contributions to clinical heterogeneity. Which models to
combine will ultimately be dependent on the scientific question
being asked. By mapping existing models onto different stages of
human disease, appropriate systems can be selected to investi-
gate major steps in disease initiation and progression. Additional
benefits of this type of mapping are to highlight knowledge gaps
in pathogenesis and hence where new models may be required.
The generation of a comprehensive RA pathogenesis map will
require in-depth analysis of existing models and will rely heavily
on generation of detailed standardised protocols. The importance
of developing pathogenesis maps, the refinement and standardis-
ation of current models and ethical considerations have recently
been discussed in detail elsewhere [8, 9]. Descriptions of the mod-
els discussed in this article can be found in Table 1.
In addition to the clear definition of models relevant to spe-
cific disease stages, there must be greater appreciation of pro-
cesses regulating transition from stage to stage. While key cells
and molecules contributing to pathology have been highlighted,
we lack knowledge pertaining to the underlying dynamics of the
immune response. Candidate triggers can be highlighted by cor-
relative patient studies but the development of current and new
models will be critical in defining mechanisms by which they drive
pathogenesis.
Breach of self-tolerance
With successes in the treatment of established RA, one critical
therapeutic objective is now restoration of antigen-specific toler-
ance in RA [12–14] and associated drug free remission. A hurdle
in developing such revolutionary therapeutics is our lack of mech-
anistic understanding of breach of self-tolerance and a paucity of
arthritis models allowing detailed analysis of processes that regu-
late tolerance in vivo.
Critical roles for the adaptive immune system in the develop-
ment of RA are supported in part by predisposing genetic traits. In
addition to the long-standing association with human leukocyte
antigen (HLA)-DR4 alleles, genome wide scanning studies impli-
cate ptpn22, cd40, ctla4 and cd28 in disease pathogenesis. Yet a
comprehensive picture integrating these susceptibility loci with
mechanisms leading to breach of self-tolerance in preclinical RA
is lacking.
HLA class II transgenic mice
HLA class II mouse models are relevant to initial breach of tol-
erance mechanisms including shaping of the TCR repertoire and
profiling T cell epitopes arising from autoantigens [15]. Similar
MHC class II associated pathogenesis is seen in collagen induced
arthritis (CIA) [16] where susceptibility is linked with the H2-Aq
haplotype [17].
PTPN22 polymorphisms
Models of additional risk associated alleles include those relating
to polymorphisms in protein tyrosine phosphatase non-receptor
type 22 (PTPN22). PTPN22 encodes lymphocyte tyrosine phos-
phatase (Lyp), with the 1858 C to T polymorphism representing
one of the highest risk associations after HLA class II [18, 19].
Lyp functions as a critical negative regulator of T cell receptor
signal transduction and is thus poised to influence the outcome
of T cell recognition of cognate antigen. Several approaches to
developing murine models to assess the contribution of this risk
allele include Ptpn22 knockout, knock in of Ptpn22-R619W (anal-
ogous to the human polymorphism) and transgenic overexpres-
sion of the human risk variant (Lyp620W). Details of these models
have recently been reviewed, describing specific immune pertur-
bations and parallels to human disease [19]. Despite discrepancies
between the models, they do provide a platform to assess altered
antigen receptor responsiveness, thymic selection, T cell differen-
tiation and ultimately breach of self-tolerance driving the contri-
bution of ptpn22 polymorphisms to RA pathogenesis. Yet these
risk allele models do not spontaneously develop overt arthritis
unless in the context of an additional autoreactive TcR transgene
or injection of arthritogenic antigen in adjuvant. Additional fac-
tors are required to work in tandem with genetic predispositions
in the development of autoimmune T and B cell responses.
SKG mice
SKG mice, which carry a point mutation of ZAP70 gene, spon-
taneously develop chronic autoimmune arthritis stemming from
altered TcR signaling and consequent perturbations in thymic
selection events. Notably, these arthritis prone mice require envi-
ronmental triggers for disease onset. Rearing of SKG mice in
specific pathogen-free or germ-free conditions requires fungal or
intestinal microbiota respectively to establish the development of
arthritis [20–22]. Similar observations have been made in other
models including IL-1 receptor antagonist deficient (IL-1RA−/−)
[23] and K/BxN mice [24], providing platforms for defining
C© 2017 The Authors. European Journal of Immunology published by
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Table 1. Characteristics of selected animal models
Model Brief description
Collagen induced arthritis (CIA) Induced by intradermal immunisation with type II collagen (CII) emulsed in CFA.
Incidence and chronicity depend on susceptibility of mouse strain and the CII being
used (heterologous or homologous). H-2q confers disease susceptibility. Use of
homologous CII induced relapsing/chronic arthritis. Both autoreactive anti-CII T and
B cells are mounted.
HLA class II transgenic mice Several HLA class II transgenic mice have been generated using different risk and
protection associated loci – see [15].
SKG mouse Development of inflammatory arthritis associated with a point mutation in ZAP-70. T cell
mediated disease but also relies upon presence of microflora. Mice develop autoreactive
T and B cell responses.
IL-1RA−/− mouse Deficiency of IL-1 receptor antagonist results in spontaneous destructive arthritis. Disease
is IL-17 and T cell dependent.
K/BxN mouse Generated by crossing a TcR transgenic specific for a bovine pancreatic ribonuclease
peptide with NOD mice. Resulting mice display T and B cell responses to
glucose-6-phosphate isomerase (G6PI).
F759 mouse Homozygous mutation in the gp130 IL-6 receptor subunit results in inflammatory
destructive arthritis. Disease is CD4 T cell dependent, but does not rely on autoreactivity.
Collagen antibody induced
arthritis (CAIA)
Induced using cocktail of anti-CII antibodies and LPS. Results in a self-limiting
polyarthritis. Inducible in most strains of mice.
K/BxN serum transfer mouse
model
Serum from K/BxN mice induces transient arthritis is various mouse strains including
C57BL/6 and BALB/c. Is T and B cell independent.
TNFα transgenic mice Several TNFα-transgenic mouse lines develop chronic progressive polyarthritis. Responses
are independent of T and B cells.
Antigen induced arthritis (AIA)
mouse model
Induced by immunisation with methylated bovine serum albumin (mBSA) in CFA followed
by articular challenge with mBSA alone. Inflammation of the challenged joint only. A
variation using adoptive transfer of Th1 TcR transgenic T cells specific for ovalbumin
(OVA) and challenge with OVA has similar effects but demonstrates evidence of anti-CII
T and B cell responses. In both instances Inflammation is self-resolving.
mechanisms of interplay between intestinal dysbiosis and genetic
susceptibility. Additional evidence of possible microbial contribu-
tion to RA development is seen in the clinical links between peri-
odontal disease and arthritis severity. Notably, prior oral infection
with Porphyromonas gingivalis was seen to accelerate joint inflam-
mation and systemic markers of inflammation in CIA [25] and
SKG mice [26]. Mechanisms pertaining to P. gingivalis exacerba-
tion of RA are unclear. However, it is postulated that P. gingivalis
infection contributes to autoreactivity through post-translational
modification of proteins and the development of antibodies against
citrullinated peptides (ACPA) [25], a predictive factor in develop-
ment of RA [4].
The lung has been implicated as an important site mediat-
ing environmental contributions to pathogenesis. Notably, smok-
ers are at a higher risk of developing RA and once afflicted will
progress more aggressively [27]. Smoking and urban pollution
can also promote post-translational modifications of self-proteins
resulting in production of ACPA and anti-carbamylated proteins
(anti-CarP), both associated with more severe joint damage [27].
To date only tentative steps have been made in modeling the role
airways have in mediating the breach of tolerance and RA [28].
While intranasal delivery of cigarette smoke extract (CSE) was
shown to augment development of CIA [29, 30], long-term expo-
sure to cigarette smoke and nicotine delayed CIA onset [31]. Rea-
sons for this discrepancy are unclear as yet. Gathering important
immunological data from such models is paramount in under-
standing the aetiological role of cigarette smoking in breach of
self-tolerance. The combination of experimental lung models with
experimental arthritis is an important area for development.
Clearly genetic susceptibility alone is insufficient for the
development of autoreactivity. Environmental contributions such
as mucosal damage, microbiome perturbations and/or chemi-
cal/microbial mediated post-translational protein modifications
contribute to RA risk. Animal models represent an important
opportunity to combine these aspects in a fuller exploration of
preclinical pathogenesis concepts.
Synovitis and articular damage
It is clear that patients can exhibit the preclinical autoimmune
phenotype for many years in an essentially asymptomatic state.
Yet the cues that drive the transition to overt articular inflam-
mation and the mechanisms of immune cell accumulation in the
joint remain enigmatic. Biomechanical stress, hypoxia and trauma
have been proposed as important factors in transition to artic-
ular localization. Physical trauma has been reported as being
C© 2017 The Authors. European Journal of Immunology published by
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significantly associated with RA onset [32], consistent with this,
physical damage to joints can drive arthritis in murine models.
F759 mice
Direct joint damage and consequent microbleeding facilitate
arthritis development in mice expressing a variant of the IL-6
signaling transducer gp130 [33]. Although T cell accumulation
in the joint is prerequisite for arthritis development in these mice,
recognition of cognate antigen is not. This may initially seem at
odds with evidence for autoreactivity driving RA. However, our
own studies using an adoptive transfer model of early arthropathy
reveals antigen driven arthritis also results in similar accumulation
T cells unrelated to joint antigen (Benson RA unpublished data).
It is therefore tempting to speculate that autoantigen driven joint
inflammation can result in innate recruitment of memory T cells
and their non-specific activation as in the instance of cytokine
activated T cells (Tck) [34].
Collagen induced arthritis (CIA) and serum transfer
models (CAIA & K/BxN)
Deposition of immune complexes in articular surfaces has a
clear role in promoting local inflammation and recruitment of
immune cells. Recent studies employing CIA implicate key roles
for Th17 helper activity in suppressing sialtransferase activity in
B cells [35]. The resulting switch in glycosylation of the Fc com-
ponent of autoantibodies produces immune complexes able to
enhance osteoclastogenesis and the beginning of articular erosions
[5, 35, 36]. The further impacts of immune complexes on various
aspects of immune pathology are reproducibly seen in collagen-
antibody–induced arthritis (CAIA) [37] and K/BxN serum trans-
fer [38] models where high autoantibody titres are readily achiev-
able. These models allow dissection of innate pathways that seed
articular inflammation and drive tissue degradation. They have
revealed the dynamic response to immune complex formation,
the activation of complement activation, neutrophil and mono-
cyte recruitment, mast cell degranulation and contributions of
TNFα, IL-6 and IL-1. As recipient mice do not develop endogenous
T and B cell autoimmune responses, only acute self-resolving dis-
ease develops. However, onset is rapid with a high penetrance
and is MHC class II haplotype independent, making these models
compatible with various genetically modified strains.
Established/chronic disease
Chronic joint inflammation is one of the hallmarks of clinical
disease, with the majority of patients presenting at this stage.
A picture of key cellular and soluble mediators is beginning to
emerge based on the success of several biologics such as anti-
CD20, CTLA4-Ig and TNFα. Despite this, there is a paucity of
models displaying chronic disease hampering mechanistic study.
TNF transgenic mice
TNF-overexpressing mice are consistently reported as developing
chronic pathology with several lines contributing to our under-
standing of TNFα activity in disease [39]. While these models
continue to be useful tools in identifying molecular mechanisms
of disease resulting from pathological TNF production [39–41]
and evaluation of therapeutic strategies [40], they do not provide
a platform to study adaptive contributions to chronicity. TNFARE
mice back-crossed to a RAG1−/− background still develop erosive
polyarthritis, indicating a key role for this cytokine downstream
of T and B cell responses [42].
Chronic collagen induced arthritis
Although the CIAmodel, IL-RA−/− and SKGmice have been shown
to be T cell dependent and model chronic disease, data pertaining
to adaptive mechanisms beyond disease onset are scarce.
Activation of the adaptive immune response clearly occurs
early in disease onset, yet how T and B cells might contribute
to ongoing chronic pathology is unclear. The acute self-resolving
nature of antibody-induced models suggests that T and B cell
activity is required for ongoing production of autoantibodies. Yet
even intact models such as CIA do not readily develop chronic
disease. Induction of chronic relapsing CIA in DBA/1 mice can be
achieved by immunisation with autologous type II collagen. Anti-
body responses to particular antigenic epitopes of type II collagen
have also been implicated in development of chronic CIA [43].
C57BL/6 mice demonstrate a marked predisposition to chronic
joint inflammation in the absence of regulatory NOX2 activity.
Thus, greater temporal dissection of these models is required to
define the adaptive immune system’s contribution to chronicity.
A final aspect of chronic disease warranting deeper investi-
gation is the contribution of the articular stromal compartment.
Synovial fibroblasts (interstitial fibroblasts, macrophage-like and
fibroblast-like synovial cells), mast cells, lymphatic and blood ves-
sels, make up the joint lining and contribute to its normal func-
tion [44]. These cells undergo profound changes in response to
articular inflammation, supporting joint destruction and perpetua-
tion of inflammatory processes [44]. Synovial fibroblasts in partic-
ular have received considerable attention in orchestrating immune
cell accumulation in the synovial environment. Numerous studies
demonstrate that synovial fibroblasts support leukocyte recruit-
ment, activation and survival (reviewed in [44]) and have pro-
posed roles in the development of tertiary lymphoid structures
(TLS) seen in chronic disease [45]. The majority of data support-
ing this has been derived from in vitro work using primary human
cells, with the recent genomic profiling of mouse synovial fibrob-
lasts from TNF-Tg mice demonstrating comparison with human
data demonstrates significant commonalities [46].
Clinical observations including elevated lymphangiogenic fac-
tors in RA synovium, increased numbers of lymphatic vessels, yet
reduced lymphatic flow implicate a role for the lymphatic sys-
tem in RA pathogenesis [47]. The ability of collecting lymphatic
C© 2017 The Authors. European Journal of Immunology published by
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vessels to contract and relax (pulse) is vital to lymph drainage by
allowing the movement of fluid against pressure gradients. Stud-
ies in K/BxN mice demonstrate biphasic lymphatic activity with
enhanced lymphatic pulse rates and elevated lymph drainage seen
in acute arthritis switching to decreased lymphatic clearance dur-
ing chronicity [48]. Current theories to explain this switch centre
on the contribution of nitric oxide (NO) to lymphatic pulse. NO
production by lymphatic endothelial cells (LECs) regulates smooth
muscle cell (SMC) contractions and hence lymphatic pulse. Dis-
ruption of endothelial NO gradients by iNOS production by active
CD11b+ leukocytes and by LECs in response to TNF results in
constant relaxation of SMCs, loss of pulse and failed lymphatic
clearance [47, 49]. Thus, articular immune responses can condi-
tion the local stroma, prompting retention of inflammatory cells
and mediators, perpetuation of inflammatory processes and estab-
lishment of chronic erosive arthritis. In this regard, the additional
therapeutic targeting of stromal cells may prove necessary for the
effective resolution of RA.
Technological developments
Disease models have been extremely useful in identifying key
cell populations and molecules contributing to pathogenesis (for
extensive review see [11]). While exploitation of the rapidly evolv-
ing –omics fields offer phenotyping of arthritis models in unprece-
dented detail, the “how, when and where” of their functional char-
acterisation will require clarification. Disease mediators can have
different effects throughout the course of the response, for exam-
ple, predisposition to K/BxN arthritis depends on IL-4, yet this
cytokine is dispensable during effector stages [50]. Thus, defin-
ing the temporal impact of a mediator will facilitate its targeting
therapeutically.
Advances in bioimaging equipment and techniques are already
adding spatial and temporal information to mouse models of
arthritis. Notable examples include multiplexed longitudinal non-
invasive imaging of disease onset and progression [51–53]. Imag-
ing in this context reduces variation introduced when different
experimental animals per time point are used, thus there are obvi-
ous data quality and ethical benefits. Continued improvements in
molecular and cellular imaging techniques will also assist in defin-
ing cellular origins, fates and functions, enabling a more complete
mechanistic understanding of disease processes [54, 55].
Conclusion
Criticism of animal models lies often in their inability to fully
recapitulate all of the complex processes leading to disease. Cases
of conflicting data between mouse and human studies continue to
fuel debate ([6, 7] and discussed in the context of RA in [11]). Nev-
ertheless, important biological concepts in arthritis and autoim-
mune diseases have been conceived or tested in animal models.
The limitations and successes mean that animal models are neither
irrelevant nor that they completely model arthritis. They represent
powerful tools to be used appropriately in conjunction with human
data - defining how to apply these tools in a rational and appropri-
ate fashion is a significant scientific goal. This will allow models
to be applied within a conceptual framework where a clear prior
knowledge of the molecular interactions and cellular processes
of interest will enable informed and rational model selection. In
addition to testing disease hypotheses, mouse models enable eval-
uation of therapeutic targets and approaches [56]. This is notable
in the context of RA [57, 58] success of this is particularly evident
in the instance of TNFα targeted therapies, chiefly validating TNFα
as a target and subsequent development of a variety of drugs to
target this pro-inflammatory cytokine [59, 60]. Additional benefits
come from the aligning of pre-clinical testing with current patho-
genesis maps where relevant animal models allow the efficacy of
current and future therapeutics to be determined in the context of
different disease phases and combinations, establishing rational
therapeutic regimes.
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